Can I Take Ashwagandha with MK-677 (Ibutamoren)?

What Are These Two Compounds and Why Do People Stack Them?

MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that stimulates pulsatile release of growth hormone (GH) and, downstream, insulin-like growth factor 1 (IGF-1). It is not FDA-approved for any clinical indication. Most use is off-label by athletes, bodybuilders, and biohackers chasing improved muscle mass, sleep quality, and recovery. The compound was originally investigated by Merck for muscle wasting and GH deficiency, reaching Phase II trials before development halted.

Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen standardized to withanolides. It has been studied in peer-reviewed trials for stress reduction, cortisol lowering, testosterone support, and thyroid modulation. Unlike MK-677, it is commercially available as a supplement and is generally recognized as safe (GRAS) in food-grade doses.

People stack the two because their claimed benefit profiles appear to complement each other: MK-677 targets GH and IGF-1 axes while ashwagandha targets stress hormones and androgenic tone. The logic is superficially appealing. The endocrine reality is more complicated.

How MK-677 Works

MK-677 mimics ghrelin at the GH secretagogue receptor (GHSR-1a), triggering somatotroph cells in the anterior pituitary to release GH in a pulsatile pattern that resembles physiological secretion. A 2-year randomized controlled trial by Nass et al. (N=65) published in the Annals of Internal Medicine showed that 25 mg/day oral MK-677 significantly increased IGF-1 levels (by roughly 40% from baseline) in older adults with GH deficiency, with concomitant increases in fat-free mass [1]. GH pulses are largest at night, which is why most protocols dose MK-677 30 to 60 minutes before sleep.

How Ashwagandha Works

Ashwagandha's active withanolides inhibit the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol output and down-regulating stress-related neuroinflammatory pathways. A double-blind RCT by Chandrasekhar et al. (N=64) in the Indian Journal of Psychological Medicine found that 300 mg twice-daily KSM-66 ashwagandha root extract reduced serum cortisol by 27.9% over 60 days versus 7.9% in placebo (P<0.001) [2]. Separately, withanolide A and withaferin A appear to modulate thyroid-stimulating hormone (TSH) sensitivity and increase conversion of T4 to the active T3 form.

Is the MK-677 and Ashwagandha Interaction Pharmacokinetic or Pharmacodynamic?

The interaction is almost entirely pharmacodynamic. There is no published evidence that ashwagandha meaningfully alters the cytochrome P450 metabolism of MK-677. Both compounds act on overlapping endocrine systems rather than competing for the same enzymatic pathway.

No Significant Pharmacokinetic Overlap

MK-677's oral bioavailability is driven by intestinal absorption rather than first-pass CYP3A4 metabolism to any clinically relevant degree in the doses tested (10 to 25 mg). Ashwagandha's withanolides are primarily metabolized through glucuronidation and sulfation pathways. Natural Medicines database (the clinical evidence resource formerly called Natural Standard) rates the pharmacokinetic interaction between ashwagandha and GH secretagogues as "unknown" due to lack of direct combination studies, but does not flag a drug metabolism concern. Because MK-677 is not FDA-approved, no formal drug interaction study exists in the published literature.

Where the Real Overlap Lives

Three pharmacodynamic axes matter:

1. Cortisol and GH secretion. Cortisol is a physiological antagonist of GH signaling. High cortisol blunts GH pulses and reduces IGF-1 bioavailability. Ashwagandha's 27.9% cortisol reduction [2] may therefore create a more permissive endocrine environment for MK-677's GH secretagogue action. This could be additive in a beneficial direction, but it also means each compound's effect is amplified by the other in ways that are hard to predict at an individual level without lab monitoring.

2. Testosterone. A 2019 RCT in Medicine (N=50 men) found that 600 mg/day ashwagandha root extract raised serum testosterone by 17% over 8 weeks compared to placebo (P<0.001) [3]. MK-677 does not directly raise testosterone, but elevated IGF-1 from MK-677 may support Leydig cell function over time, creating a modest additive androgenic signal. Neither effect is large enough to cause hyperandrogenism in healthy adults at standard doses, but men with hormone-sensitive conditions should confirm baseline testosterone before starting.

3. Thyroid hormones. This is the most clinically meaningful interaction in the stack. Ashwagandha has been shown in a 2019 pilot RCT (N=50) published in the Journal of Alternative and Complementary Medicine to raise T3 by 41.5% and T4 by 19.6% over 8 weeks in subclinically hypothyroid adults [4]. MK-677, through elevated GH and IGF-1, can suppress TSH in a dose-dependent manner at 25 mg/day, particularly during the first 6 to 12 weeks of use. The combined thyroid signal (ashwagandha pushing T3/T4 up, MK-677 suppressing TSH) could result in a dissociated thyroid panel that looks like central hypothyroidism or mild subclinical hyperthyroidism depending on the individual's baseline thyroid function.

Anyone with a history of Hashimoto's thyroiditis, Graves' disease, or on levothyroxine should have a full thyroid panel (TSH, free T3, free T4, anti-TPO antibodies) before combining these compounds.

Cortisol Modulation: Additive Benefit or Risk?

Both MK-677 and ashwagandha independently reduce cortisol, though through completely different mechanisms. Ashwagandha acts on the HPA axis centrally. MK-677 has been reported to modestly lower 24-hour cortisol area-under-the-curve in clinical subjects, a finding noted in the Nass et al. Trial [1].

The GH-Cortisol Axis

Chronic high cortisol states suppress GH secretion by increasing somatostatin tone at the hypothalamus. By reducing cortisol, ashwagandha may reduce somatostatin tone, giving MK-677 a more receptive pituitary environment. This is the theoretical basis for the "synergistic" claim you will find on bodybuilding forums. Mechanistic plausibility exists, but no human RCT has tested this combination directly.

When Cortisol Suppression Goes Too Far

Excess cortisol suppression is not benign. Cortisol below normal range can impair immune response, reduce blood pressure regulation, and cause fatigue that resembles adrenal insufficiency. The combination is unlikely to cause frank adrenal suppression at standard doses (300 to 600 mg ashwagandha extract plus 10 to 25 mg MK-677), but the risk is non-zero in individuals who are already under significant physiological stress, are using other cortisol-lowering agents, or have underlying adrenal disorders.

A morning serum cortisol drawn before any supplements is a reasonable precaution if you plan to run this stack for more than 8 weeks.

Sleep Quality: One Area Where This Stack May Perform Well

MK-677 consistently improves slow-wave sleep (SWS) duration. A crossover RCT by Copinschi et al. (N=9) showed that a single 25 mg dose of MK-677 increased SWS by 50% compared to placebo in young adults [5]. Ashwagandha independently improves sleep quality through GABA-A receptor modulation; a 2019 double-blind RCT (N=60) in PLOS ONE found that 300 mg KSM-66 twice daily improved Pittsburgh Sleep Quality Index (PSQI) scores by 72% more than placebo after 10 weeks [6].

Combining compounds that independently improve SWS and sleep architecture may produce additive sleep benefits, which in turn sustains overnight GH pulsatility. GH secretion is highest during stage 3 sleep. Better sleep architecture means more GH released per pulse cycle, independent of MK-677's direct ghrelin-receptor action.

The clinical framework HealthRX uses for evaluating sleep-support stacks rates this combination as "low interaction risk, potential additive benefit" based on these distinct mechanisms (GABAergic + GH axis) that do not compete.

Insulin Sensitivity: The Most Important Safety Concern

MK-677's most clinically significant adverse effect is insulin resistance. The Nass et al. 2-year trial [1] found that participants on 25 mg/day MK-677 had statistically significant increases in fasting blood glucose and HbA1c compared to placebo, leading the authors to caution against use in individuals with impaired glucose tolerance. This is a well-replicated finding across MK-677 studies.

Ashwagandha's Modest Glucose-Lowering Effect

Ashwagandha has a small but consistent anti-diabetic signal. A meta-analysis published in PLOS ONE (7 RCTs, N=362) found that ashwagandha supplementation reduced fasting blood glucose by a mean of 13.6 mg/dL and HbA1c by 0.45% compared to placebo [7]. This does not fully offset MK-677's glucose-raising effect, but it may partially attenuate it.

Practical Implication

Do not interpret ashwagandha's glucose benefit as a license to ignore MK-677's glycemic risk. Fasting glucose should be checked at baseline, at 8 weeks, and every 3 months during ongoing use. Anyone with a fasting glucose above 100 mg/dL (pre-diabetes threshold per the ADA) [8] should consult a physician before starting MK-677 regardless of any co-supplementation.

Dosing Windows and Practical Protocol

No pharmacokinetic separation window is required because the interaction is pharmacodynamic. You do not need to take them hours apart to avoid a metabolic collision. Aligning both compounds with the same evening schedule makes adherence simpler and may use the combined sleep-quality benefit.

A Practical Starting Protocol

• MK-677: 10 to 25 mg orally 30 to 60 minutes before sleep. Most protocols start at 10 mg for the first 2 weeks to assess tolerability, especially regarding water retention and appetite stimulation.
• Ashwagandha: 300 to 600 mg standardized root extract (5% withanolides or KSM-66/Sensoril) with the evening meal or alongside MK-677. Twice-daily dosing (morning and evening) is used in the trials with the largest cortisol-reduction effects.
• Cycle length: Most published MK-677 trials run 8 to 24 weeks. Ashwagandha can be taken continuously or cycled 8 weeks on, 2 to 4 weeks off.
• Lab monitoring schedule: Baseline before starting, repeat at 8 weeks (TSH, free T3, fasting glucose, IGF-1, serum cortisol AM, total and free testosterone in men).

Who Should Not Combine These Compounds

• Active thyroid disease (Hashimoto's, Graves') without physician oversight.
• Pre-diabetes (fasting glucose 100 to 125 mg/dL) or type 2 diabetes.
• Pregnancy or breastfeeding. Ashwagandha is contraindicated in pregnancy [9] and MK-677's reproductive safety profile is entirely unstudied in humans.
• Autoimmune conditions. Ashwagandha may stimulate Th1 immune responses; immunosuppressed patients or those with active autoimmune disease should avoid it [9].
• Age <18. Neither compound has pediatric safety data.

What Clinicians Say About GH Secretagogues and Adaptogen Stacking

Endocrine Society guidelines on growth hormone deficiency in adults (2019 update) state that "GH therapy should not be initiated without comprehensive biochemical confirmation of GHD" and note that GH secretagogues used outside of supervised clinical trials lack the evidence base to justify routine use [10]. The guidelines do not specifically address adaptogen co-administration because the clinical literature predates widespread GH secretagogue use in non-clinical populations.

On the ashwagandha side, a 2023 consensus position from the American Botanical Council's expert panel noted that "evidence is sufficient to support ashwagandha's adaptogenic and anxiolytic effects at doses of 300 to 600 mg daily standardized extract, with a favorable short-term safety profile in healthy adults." Short-term here means studies up to 12 weeks, which is the duration covered by most of the RCT literature.

No guideline organization has formally evaluated the MK-677 plus ashwagandha combination because no direct combination trial has been published. The absence of a safety signal in published case reports does not mean the combination is proven safe; it means data are sparse.

Monitoring Checklist Before and During the Stack

Getting labs before you start is not optional if you want to run this responsibly. The following panel gives your clinician a baseline to interpret any symptoms that arise.

Before starting:

• Fasting glucose and HbA1c
• IGF-1 (morning, fasted)
• TSH, free T3, free T4
• Total testosterone and free testosterone (men)
• AM serum cortisol (drawn before 9 AM, before any supplements)
• Comprehensive metabolic panel (CMP)

At 8 weeks:

• Repeat all of the above
• Blood pressure (MK-677 can increase fluid retention and transiently affect BP)
• Note sleep quality, appetite changes, and joint discomfort (common MK-677 side effects)

Red flags to stop and consult a physician:

• Fasting glucose rising above 126 mg/dL on two separate readings
• TSH falling below 0.4 mIU/L or rising above 4.5 mIU/L
• Symptomatic cortisol excess (central weight gain, new stretch marks, hypertension) or cortisol deficiency (fatigue, hypotension, hypoglycemia)
• Paresthesias in hands or feet (carpal tunnel is a documented MK-677 side effect at 25 mg)

Summary of the Interaction Profile

The table below consolidates the interaction axes discussed above.

| Axis | Ashwagandha Effect | MK-677 Effect | Combined Signal | |---|---|---|---| | Cortisol | Reduces (HPA axis) | Modest reduction | Additive lowering; monitor AM cortisol | | GH pulsatility | Indirect boost via cortisol reduction | Direct GHSR-1a agonism | Potentially additive | | IGF-1 | No direct effect | Raises ~40% | MK-677 dominant | | Testosterone | Raises ~17% (men) | IGF-1 support, indirect | Mild additive signal | | Thyroid (T3/T4) | Raises T3 +41.5%, T4 +19.6% | TSH suppression at 25 mg | Dissociated panel risk; monitor | | Fasting glucose | Modest reduction (~13.6 mg/dL) | Raises; insulin resistance risk | Partial offset; monitor closely | | Sleep quality | SWS via GABA-A | SWS via GH pulse | Additive; low interaction risk |